[Click eStock] "Celltrion Healthcare, Quarterly Operating Profit of Over 30 Billion KRW... Strong Performance Expected to Continue"

[Asia Economy Reporter Park Jihwan] NH Investment & Securities analyzed on the 14th that Celltrion Healthcare is expected to surpass quarterly operating profit of 30 billion KRW for the first time in two years. The investment opinion 'Buy' and target price of 67,000 KRW were maintained.

Researcher Koo Wan-sung of NH Investment & Securities stated, "Consolidated sales for the fourth quarter of last year are expected to be 295.7 billion KRW, a 56.7% increase compared to the same period last year, and operating profit is expected to turn positive at 34.8 billion KRW," adding, "Although sales deferral due to adjustments in the European channel is inevitable, the start of exports of Truxima and Herzuma to the U.S. and sales growth of Herzuma in Japan are positive."

Researcher Koo Wan-sung analyzed, "This year's expected performance is sales of 1.4369 trillion KRW, a 32.7% increase compared to the same period last year, and operating profit of 193.3 billion KRW, a 158.4% increase," adding, "There are multiple research and development (R&D) momentum factors such as the submission of the European approval application for CT-P17 (next-generation Humira biosimilar) in the first quarter and the European launch of Remsima SC in the second quarter."

This content was produced with the assistance of AI translation services.